These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37762484)

  • 1. Modeling Myotonic Dystrophy Type 2 Using
    Marzullo M; Coni S; De Simone A; Canettieri G; Ciapponi L
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (CCUG)
    Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A
    Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy.
    Wei C; Stock L; Schneider-Gold C; Sommer C; Timchenko NA; Timchenko L
    Mol Cell Biol; 2018 Jul; 38(14):. PubMed ID: 29735719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational control of polyamine metabolism by CNBP is required for
    Coni S; Falconio FA; Marzullo M; Munafò M; Zuliani B; Mosti F; Fatica A; Ianniello Z; Bordone R; Macone A; Agostinelli E; Perna A; Matkovic T; Sigrist S; Silvestri G; Canettieri G; Ciapponi L
    Elife; 2021 Sep; 10():. PubMed ID: 34517941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patients.
    Santoro M; Fontana L; Maiorca F; Centofanti F; Massa R; Silvestri G; Novelli G; Botta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):917-924. PubMed ID: 29291944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myotonic Dystrophies: A Genetic Overview.
    Soltanzadeh P
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting Pathogenetic Mechanisms and Therapeutic Strategies in
    Souidi A; Zmojdzian M; Jagla K
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30567354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes.
    Cerro-Herreros E; Chakraborty M; Pérez-Alonso M; Artero R; Llamusí B
    Sci Rep; 2017 Jun; 7(1):2843. PubMed ID: 28588248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of muscle atrophy in myotonic dystrophies.
    Timchenko L
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myotonic dystrophy type 2: the 2020 update.
    Meola G
    Acta Myol; 2020 Dec; 39(4):222-234. PubMed ID: 33458578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flies deficient in Muscleblind protein model features of myotonic dystrophy with altered splice forms of Z-band associated transcripts.
    Machuca-Tzili L; Thorpe H; Robinson TE; Sewry C; Brook JD
    Hum Genet; 2006 Nov; 120(4):487-99. PubMed ID: 16927100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myotonic dystrophy type 2 and related myotonic disorders.
    Meola G; Moxley RT
    J Neurol; 2004 Oct; 251(10):1173-82. PubMed ID: 15503094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2.
    Perfetti A; Greco S; Fasanaro P; Bugiardini E; Cardani R; Garcia-Manteiga JM; Riba M; Cittaro D; Stupka E; Meola G; Martelli F
    PLoS One; 2014; 9(4):e93983. PubMed ID: 24722564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.
    Meola G; Cardani R
    Biochim Biophys Acta; 2015 Apr; 1852(4):594-606. PubMed ID: 24882752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
    Meola G
    Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2.
    Kamsteeg EJ; Kress W; Catalli C; Hertz JM; Witsch-Baumgartner M; Buckley MF; van Engelen BG; Schwartz M; Scheffer H
    Eur J Hum Genet; 2012 Dec; 20(12):1203-8. PubMed ID: 22643181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.
    Day JW; Ricker K; Jacobsen JF; Rasmussen LJ; Dick KA; Kress W; Schneider C; Koch MC; Beilman GJ; Harrison AR; Dalton JC; Ranum LP
    Neurology; 2003 Feb; 60(4):657-64. PubMed ID: 12601109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
    Mankodi A; Urbinati CR; Yuan QP; Moxley RT; Sansone V; Krym M; Henderson D; Schalling M; Swanson MS; Thornton CA
    Hum Mol Genet; 2001 Sep; 10(19):2165-70. PubMed ID: 11590133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
    Cho DH; Tapscott SJ
    Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.
    Sellier C; Cerro-Herreros E; Blatter M; Freyermuth F; Gaucherot A; Ruffenach F; Sarkar P; Puymirat J; Udd B; Day JW; Meola G; Bassez G; Fujimura H; Takahashi MP; Schoser B; Furling D; Artero R; Allain FHT; Llamusi B; Charlet-Berguerand N
    Nat Commun; 2018 May; 9(1):2009. PubMed ID: 29789616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.